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Metastasis occurs when cancer cells leave the primary tumor site and migrate to distant parts of the
body. The CXCR4–SDF-1 pathway facilitates this migration, and its expression has become the hallmark
of several metastatic cancers. Targeted approaches are currently being developed to inhibit this pathway,
and several candidates are now in clinical trials. Continued exploration of CXCR4 inhibitors will generate
compounds that have improved activity over current candidates.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Cells do not stand still. Cell migration is a primordial character-
istic observed from the beginning of embryonic development, and
directed cell movement continues throughout the life of an organ-
ism.1 During normal mammalian embryogenesis, embryonic stem
cells (ESCs) trafﬁc to numerous sites under the control of several
chemokines, including stromal cell-derived factor-1 (SDF-1; also
known as CXCL12) and its corresponding adhesive molecule CXCR4
(CD184).2,3 Adult pluripotent cells maintain a ‘homing’ capacity to
speciﬁc tissues using the SDF-1/CXCR4 chemosensory system,
leading to life-afﬁrming effects such as wound repair and tissue
regeneration.4–6
Cancer cells exploit the same migratory pathways utilized by
embryonic and adult stem cells.7,8 Metastatic tumors express ESC
transcription factors and spread beyond the primary tumor site
through SDF-1/CXCR4-mediated migration.9 Expression of CXCR4
has been tied to tumor inﬁltration and poor prognosis in colon,
breast, and gallbladder cancers.10–13 In addition, SDF-1 expression
is correlated to reduced survival in ovarian cancer patients.11 A
growing body of research points to the CXCR4 pathway as an
emerging arena for cancer drug discovery, with the goal of specif-
ically disrupting the receptor-ligand (CXCR4–SDF-1) interaction
that drives the spread of tumors. In addition, a deeper understand-
ing of the pathways involved in CXCR4 folding and expression
points to the major role that molecular chaperones play in facilitat-
ing metastasis.14 Current therapies being tested in clinical trials are
utilizing a combinatorial approach for inhibiting the spread of
CXCR4-expressing cancer cells, targeting both the receptor-ligand
interaction and other pro-oncogenic pathways (Table 1).x: +61 2 9385 6141.
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-NC-ND license.CXCR4 is a member of the G protein-coupled (GPC) chemokine
receptor family, utilizing seven trans-membrane alpha helices to
integrate into the cell membrane (Fig. 1). CXCR4 gene expression
is downregulated in normal breast cells and non-invasive cancer
cell lines, but invasive neuroblastoma and prostate cancer cell lines
show high levels of CXCR4 transcription.15,16 Several factors may
contribute to the observed increase in gene expression, such as
DNAmethylation or TNF signaling cascades.17,18 In addition, upreg-
ulation of the transcriptional activator HIF-1a leads to a direct in-
crease in CXCR4 gene expression.19 Following post-translational
modiﬁcation, CXCR4 relies on the molecular chaperone heat shock
protein 90 (Hsp90) for proper folding and delivery to the lipid bi-
layer (Fig. 2).14 Hsp90 is also the molecular chaperone for several
members of the CXCR4/SDF-1 phosphorylation cascade, including
the protein tyrosine kinase Src, human epidermal growth factor
receptor 2 (HER2), and the serine/threonine kinase Akt.21,22 Inhib-
itors of Hsp90 have been studied in clinical trials for efﬁcacy
against metastatic cancers,14 and expression levels of several pro-
teins in the CXCR4 pathway are reduced during treatment.23 How-
ever, toxicity issues limit the use of current Hsp90 inhibitors as a
monotherapy in the clinic.23
The crystal structure of CXCR4 shows that the seven trans-
membrane alpha helices bundle together to form an extracellular
binding pocket (Fig. 124). The extracellular loops (ECLs) and amino
acids within the alpha helices contribute to binding interactions
with potential ligands. Two disulﬁde bonds form between key cys-
teine residues on the extracellular face of the receptor, and these
bonds are critical for shaping the binding pocket and for ligand
binding: Cys28 of the N-terminal segment with Cys274 of helix
VII (H7), and Cys109 with Cys186 in ECL2.20,24 CXCR4 can
also homo- or heterodimerize.20,25 This ability could facilitate
metastasis in cancer cells expressing high levels of CXCR4, since
Table 1
Selected CXCR4 and SDF-1 Inhibitors in clinical triala
Sponsor Drug
name




MDX-1338, Medarex Lenalidomide, Dexamethasone, or
Bortezomib
IA Multiple myeloma
Ablynx ALX-0651 I Healthy volunteers (safety study)
CXCR4 antagonists
Biokine Therapeutics Ltd BKT-140 4F-benzoyl-TN14003,
BL-8040
I/IIA Multiple myeloma
Cardiff University Plerixafor Mozobil, Genzyme,
AMD3100
Daunorubicin, Clofarabine I Acute myeloid leukemia; high risk
myelodysplastic syndrome






I/II Acute myeloid leukemia




Decitabine I Acute myeloid leukemia
Metastatix, Inc. MSX-122 I Refractory metastatic or locally advanced
solid tumors
SDF-1 antagonists
Noxxon Pharma AG NOX-A12 II Multiple myeloma
a Information obtained from www.clinicaltrials.gov.
Figure 1. CXCR4 receptor structure and binding pocket. CXCR4 consists of seven trans-membrane helices (H1–7) and three extracellular loops (ECL1-3). The receptor folds
into a bundle, creating a binding pocket for its ligand SDF-1.21
Figure 2. CXCR4/SDF-1 signaling cascade. CXCR4 is folded and delivered to the cell surface by Hsp90. Once the chemokine SDF-1 is bound, a phospho-relay transfers the
signal to Akt, leading to actin reorganization and subsequent cell migration.
D. M. Ramsey, S. R. McAlpine / Bioorg. Med. Chem. Lett. 23 (2013) 20–25 21dimerization would amplify the signaling cascade upon ligand
binding and lead to enhanced downstream effects. Crystal struc-
tures of CXCR4 homodimers indicate that ligand-induced confor-mational changes to one receptor can actually increase the ligand
binding afﬁnity of a second receptor.20 The converse is also true,
suggesting that the biological efﬁcacy of CXCR4 antagonists may
Figure 3. Anti-CXCR4 antibodies and nanobodies bind to the CXCR4 receptor and
block SDF-1 from entering the binding pocket.
22 D. M. Ramsey, S. R. McAlpine / Bioorg. Med. Chem. Lett. 23 (2013) 20–25be tied to whether these modulators induce positive or negative
binding cooperativity.
The small chemokine SDF-1 binds CXCR4 and other cognate
receptors (Fig. 1), triggering multiple signaling cascades that pro-
mote cell survival and metastasis.16,26 The source of SDF-1 can be
normal tissue (including blood vascular endothelial cells and bone
marrow), stromal cells within solid tumors (for paracrine signal-
ing), or cancer cells themselves (for autocrine signaling).27–29 The
crystal structure of SDF-1a consists of two monomers that form
an asymmetrical dimer.30 Each monomer is composed of three beta
strands that form an anti-parallel beta sheet, which is bordered on
either side by an alpha helix. The N-terminal amino acids of SDF-1
are thought to be responsible for its ligand binding activity.30
Charged residues within the ﬁrst alpha helix and the beta sheet,
as well as an adjacent hydrophobic region within the beta sheet,
may facilitate interactions with the trans-membrane helices of
CXCR4.
Once SDF-1 is bound, CXCR4, HER2, and possibly extracellular
Hsp90, co-localize to lipid rafts, which are cell membrane clusters
enriched in cholesterol.31 Not only do lipid rafts facilitate transfer
of the signal into the cell interior, but recent evidence suggests that
extracellular Hsp90 stabilizes HER2 and promotes this signaling
event (Fig. 2).22,31 Once bound to SDF-1, activated CXCR4 increases
intracellular calcium levels and induces a phosphorylation cas-
cade.32 CXCR4 is then internalized and can be recycled back to
the cell surface or degraded by lysosomal enzymes.32
Cell motility is regulated at the intracellular level by several
phosphorylation cascades controlled by Src or Akt (also called pro-
tein kinase B). Akt serves as the central node in the CXCR4/SDF-1
signaling cascade (Fig. 2). Association with Hsp90 protects Akt
from dephosphorylation and subsequent degradation. Akt phos-
phorylates the G protein Girdin and other downstream targets that
modulate reorganization of actin ﬁbers in the cell.33,34 Actin poly-
merization is further stabilized by Hsp90, leading to the formation
of plasma membrane protrusions known as ﬁlopodia.35,36 Thus, tu-
mor cells utilize the CXCR4/SDF-1 signaling cascade to induce actin
polymerization and directed cell migration, and CXCR4-positive
cancer cells take advantage of autocrine or paracrine-generated
SDF-1 gradients to spread to other tissues.
The strategic approach to blocking the CXCR4/SDF-1 pathway
has centered largely on inhibitors of the receptor CXCR4 or the che-
mokine SDF-1. CXCR4 inhibitors fall into two categories: anti-
CXCR4 antibodies and CXCR4 antagonists (Table 1). Since CXCR4
is also the co-receptor for human immunodeﬁciency virus (HIV)
and is required for viral entry into T cells, signiﬁcant drug design
advancements on CXCR4 inhibitors were made before they were
utilized as anti-cancer therapies. Chemokine inhibitors are gener-
ally well tolerated by patients, and antagonists of SDF-1 are now
exhibiting some success in clinical trials.37,38 In addition, targeting
other extracellular proteins in the CXCR4 pathway (namely HER2)
has also shown some therapeutic promise in inhibiting metastasis
and could be combined in future studies with CXCR4/SDF-1
antagonists.39
Anti-CXCR4 antibodies. Amino acids within the CXCR4 binding
pocket form speciﬁc interactions with SDF-1, but the receptor as
a whole is quite ﬂexible and can dislodge the binding of large mol-
ecules such as monoclonal antibodies that target its surface.40,41 As
a result, anti-CXCR4 antibodies must form strong binding interac-
tions with CXCR4 to form a physical barrier to chemokines
attempting to enter the binding pocket (Fig. 3). A recent study
examining CXCR4/SDF-1 interactions found that sulfonated tyro-
sine residues in one of the N-terminal extracellular loops of CXCR4
are absolutely critical for binding to SDF-1.42 Targeting these spe-
ciﬁc sulfonated tyrosine residues has proven an effective strategy
for neutralizing the effects of chemokine-receptor interactions
and avoiding the issues associated with monoclonal antibodies tar-geted to ﬂexible regions on CXCR4. The current anti-CXCR4 anti-
body under clinical investigation is the drug candidate MDX-
1338 (BMS-936564).40 MDX-1338 directly blocks the binding
interaction between one of the N-terminal extracellular loops of
CXCR4 and SDF-1, causing inhibition of cell migration.43 MDX-
1338 is potent in the low nanomolar range and reduces AML tu-
mors in murine xenograft models.43 Clinical studies are ongoing,
where MDX-1338 is used in combination with standard chemo-
therapeutic treatments to reduce multiple myeloma (MM;
Table 1).
One of the drawbacks of monoclonal antibody therapy is that
multiple antibodies must be used to target multiple epitopes on
a single receptor. Advancements in nanotechnology have led to
the development of a unique solution: the nanobody. Nanobodies
are antibody fragments with a single monomeric variable domain
(monovalent), or two different variable domains held together by
a ﬂexible linker (biparatopic).44 Only four nanobodies are currently
being studied in clinical trials, and one of those nanobodies (ALX-
0651) targets CXCR4. Recent data suggests that monovalent CXCR4
nanobodies act as neutral antagonists, which compete with SDF-1
for binding but fail to neutralize multiple CXCR4 receptors at
once.44 On the other hand, biparatopic CXCR4 nanobodies are de-
signed to act as inverse agonists, not only by blocking SDF-1, but
also by inhibiting multiple CXCR4 receptors through the bivalent
construction of the molecule (Fig. 3). This cumulative effect coun-
teracts overexpression and homodimerization of CXCR4 receptors
on cancer cell surfaces and leads to downstream effects such as
inhibition of cell migration.44 ALX-0651 is a biparatopic nanobody
currently in Phase I clinical trials (Table 1), where there is evidence
suggesting that this molecule signiﬁcantly reduces cell migration.
Although clinical studies using ALX-0651 are just beginning, there
is considerable promise for the use of this new technology in the
development of novel anti-metastatic agents.
CXCR4 antagonists. A well-known small molecule inhibitor of
CXCR4 is AMD3100 (xylyl–bicyclam), which is currently in Phase
I/II clinical trials (Fig. 4). AMD3100 was initially studied for its anti-
viral properties, and the observation that this molecule induced
stem cell mobilization was a surprising side effect that led to the
examination of its anti-cancer activity.41 The ability of AMD3100
to act as a stem cell mobilizer has been frequently exploited in
the clinic, although its mechanism of action is under debate.6
Hematopoetic stem cells (HSCs) in the bone marrow maintain
the balance between proliferation and differentiation, replenishing
both blood and immune cells in the bloodstream to keep the sys-
tem at a steady state. CXCR4-positive HSCs are retained in the bone
Figure 4. Small molecule antagonists of CXCR4.
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naling), and SDF-1 binds to CXCR4 and prevents HSC migration
outside of the niche. Clinicians can manipulate this storehouse of
stem cells for a variety of purposes, including tissue regeneration,
or by inducing cancerous stem cells to leave the marrow during
chemotherapy. For HSCs to leave the bone marrow, it is hypothe-
sized that CXCR4 antagonists such as AMD3100 work by binding
to CXCR4 and blocking the binding of endogenous SDF-1.45 With-
out the receptor’s ability to respond to its retention signal (i.e.
SDF-1 in the bone marrow niche), CXCR4-positive HSCs will leave
the marrow and enter the bloodstream.
AMD3100 is a metal-chelating, bicyclic, reversible inhibitor that
binds in a pocket between the transmembrane helices and extra-
cellular loop (ECL) 2 of CXCR4, leading to allosteric modulation
and effective blockade of SDF-1 binding (Fig. 5).46 This antagonist
is speciﬁc for the CXCR4 receptor and does not cross-react with
other GPC-receptors. AMD3100’s selectivity may be due in part
to the key hydrophobic contacts formed between the bicyclam
rings and two tryptophan residues within the binding pocket of
CXCR4, Trp 195 and Trp283.47 Several Phase I/II clinical trials are
utilizing this molecule in a combinatorial therapeutic approach
to treat acute myeloid leukemia (AML)45. Interestingly, the afﬁn-Figure 5. CXCR4 antagonists compete for binding to the receptor binding pocket. The bind
antagonists.ity of these bicyclam complexes for CXCR4 is enhanced when
the macrocycle binds to copper, nickel or zinc ions.47,48 Further
research is underway to study how metal complexes can strength-
en the CXCR4 receptor binding interactions with bicyclam
macrocycles.
New developments in small molecule inhibitors of CXCR4 have
led to some interesting leads that exhibit anti-metastatic proper-
ties. MSX-122, currently in Phase I clinical trials, is a small mole-
cule antagonist of CXCR4 that inhibits metastasis of breast,
melanoma, and head and neck carcinoma in murine models
(Fig. 4).49 There have also been recent leads in the development
of small molecules that target sites on CXCR4 other than its bind-
ing pocket. One such small molecule inhibitor is the natural prod-
uct celastrol (Fig. 4), which prevents cell migration by inhibiting
translation of CXCR4 mRNA.50 Other compounds have targeted a
post-translational modiﬁcation of CXCR4, where a recent in silico
screen identiﬁed inhibitors that bound to a sulfotyrosine recogni-
tion site within one of the N-terminal extracellular loops of
CXCR4.43 One inhibitor identiﬁed in this screen reduced SDF-1-
mediated calcium ﬂux in treated THP-1 cells.42
Peptide inhibitors of CXCR4 are beginning to show promise in
the clinic. BKT140 is an analog of T140 (sequence of T140: H-ing pocket (BP) of CXCR4 is the site for SDF-1 binding, as well as the target of CXCR4
24 D. M. Ramsey, S. R. McAlpine / Bioorg. Med. Chem. Lett. 23 (2013) 20–25Arg-Arg-Nal-Cys-Tyr-Arg-Lys-D-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-OH),
a 14-residue peptide that is a potent inverse agonist and CXCR4
antagonist and inhibits metastatic breast cancer in murine mod-
els.51 With its potency in the low nanomolar range, BKT140 is
now being studied in Phase I/II clinical trials against MM (Table 1).
Other peptide analogs have used virally-derived CXCR4 antagonists
as the basis for lead compound development. Using 21 amino acids
from the human herpesvirus 8 viral macrophage inﬂammatory pro-
tein II (vMIP-II), recent research indicates that D-amino acid analogs
of this peptide bind CXCR4 more strongly than the original peptide
and serve as better antagonists.40 These discoveries will contribute
signiﬁcantly to the design of new peptide inhibitors.
SDF-1 antagonists. SDF-1 antagonists have been studied for their
efﬁcacy in both cancer and diabetes research, and promising re-
sults have been observed.38 The common SDF-1 antagonist is a
45 base pair L-RNA oligonucleotide (or Spiegelmer) known as
NOX-A12.38 This aptamer is currently in Phase II clinical trials as
a monotherapy against MM (Table 1). One question that remains
to be explored in the clinic is whether CXCR4 antagonism alone
can halt metastasis, or whether SDF-1 antagonism is also required
for full therapeutic impact. Future clinical studies that combine
CXCR4 and SDF-1 antagonists may determine if there is an additive
beneﬁt, or if one antagonist is better at inhibiting metastatic dis-
ease and preventing relapse.
Inhibitors of other proteins in the CXCR4 pathway. The CXCR4/
SDF-1 pathway plays a major role in metastatic breast cancer,
where the overexpression of CXCR4 is one of several biomarkers
(including HER2/neu) used to diagnose aggressive disease.52 Thus,
inhibitors of other proteins in the CXCR4 pathway may be required
for optimal therapeutic effect. The role of CXCR4/SDF-1 pathway in
metastatic breast cancer has become clearer in recent years. SDF-1
can induce the transactivation of HER2/neu in breast cancer cells,53
and CXCR4 can facilitate homing of metastatic breast cancer cells
to the bone.52 More research is needed in metastatic breast cancer
clinical trials to determine the efﬁcacy of CXCR4/SDF-1 antagonists
in combination with other chemotherapeutic agents. Anti-HER2
monoclonal antibodies, either alone or conjugated to other anti-
cancer drugs (such as Trastuzumab emtansine or T-DM1), may
be needed in addition to CXCR4/SDF-1 antagonists for successful
treatment of metastatic breast cancer.54
The GPC-receptor CXCR4 and its chemokine SDF-1 play a critical
role in cell migration and metastatic disease. Beneﬁting from early
anti-viral research, the development of CXCR4 inhibitors has led to
several successful drug candidates that are currently undergoing
testing in Phase I/II clinical trials. Future development of carefully
designed agonists and antagonists, as well as mining structures
from natural product sources, will expand the number of new
anti-cancer agents with the potential to halt CXCR4-mediated cell
migration. The success of these compounds may require a combi-
nation of therapies targeted at multiple proteins involved in this
metastatic pathway.
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